- Home
- GALT vs CGEN Comparison
GALT vs CGEN Comparison
Compare GALT & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GALT | CGEN |
|---|---|---|
| Founded | 2000 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.2M | 188.2M |
| IPO Year | 2008 | 2001 |
Fundamental Metrics
Financial Performance| Metric | GALT | CGEN |
|---|---|---|
| Price | $2.46 | $2.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $8.50 | $5.00 |
| AVG Volume (30 Days) | ★ 307.8K | 280.7K |
| Earning Date | 05-14-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $112.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.22 | $1.23 |
| 52 Week High | $7.13 | $2.78 |
Technical Indicators
Market Signals| Indicator | GALT | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.01 | 79.22 |
| Support Level | $2.13 | $1.45 |
| Resistance Level | $3.32 | N/A |
| Average True Range (ATR) | 0.22 | 0.15 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 33.33 | 92.19 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.